View ValuationCabio Biotech (Wuhan) 将来の成長Future 基準チェック /06現在、 Cabio Biotech (Wuhan)の成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長28.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026お知らせ • May 24Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei ChinaBoard Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Dec 26Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Dec 03CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 ParisAt the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation.お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2025 Results on Aug 19, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • May 08Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei Chinaお知らせ • Mar 28Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025お知らせ • Jan 25Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 25 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.お知らせ • Dec 27Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥25.10, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 30% over the past year.Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.098 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥126.3m (flat on 3Q 2023). Net income: CN¥16.0m (down 37% from 3Q 2023). Profit margin: 13% (down from 20% in 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥18.54, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 1.7% over the past year.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results.お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥17.55, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 9.0% over the past year.New Risk • Sep 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.26 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥143.8m (up 30% from 2Q 2023). Net income: CN¥43.6m (up 112% from 2Q 2023). Profit margin: 30% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Aug 28Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 20 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥15.06, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 25% over the past year.お知らせ • Jun 28Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • May 18Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei ChinaValuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 34%After last week's 34% share price gain to CN¥19.65, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 11% over the past year.Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.086 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.086 in 1Q 2023). Revenue: CN¥117.0m (up 33% from 1Q 2023). Net income: CN¥24.3m (up 70% from 1Q 2023). Profit margin: 21% (up from 16% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024Reported Earnings • Feb 26Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.39 in FY 2022)Full year 2023 results: EPS: CN¥0.54 (up from CN¥0.39 in FY 2022). Revenue: CN¥445.5m (up 2.8% from FY 2022). Net income: CN¥91.5m (up 42% from FY 2022). Profit margin: 21% (up from 15% in FY 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China.New Risk • Feb 25New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (9.7% net profit margin).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥12.05, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in China.お知らせ • Dec 29Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥111.0m (up 16% from 2Q 2022). Net income: CN¥20.5m (down 23% from 2Q 2022). Profit margin: 19% (down from 28% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • May 10Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023CABIO Biotech (Wuhan) Co., Ltd. announced on May 9 to 11, 2023, the company participates in the three-day Vitafoods Europe held in Geneva, Switzerland. The company showcases three new ingredients — HMOs, Salecan® ß-glucan and elastin — as well as its already well-known ARA, algal oil DHA, ß-Carotene and sialic acid (SA) during the exhibition. HMOs, human milk oligosaccharides in full, are the significant components of breast milk and play an essential part in promoting infant brain development, maintaining intestinal microecological balance, building resistance to bacteria and viruses, and improving immunoregulation. Adult ingestion of HMOs also enhances the quality of life by contributing positively to intestinal microbiota while likely improving severe symptoms of irritable bowel syndrome (IBS). Salecan® ß-glucan is a novel water-soluble ß-glucan generated from a patented strain using the fermentation process. Approved by both FDA-GRAS and Chinese FDA New Food Ingredient Accreditation, Salecan® ß-glucan is applied extensively in food & drinks, foods for special dietary uses (FSDUs) and dietary supplements to enhance immunity, regulate intestinal microbiota, repair intestinal mucosae and improve blood lipid and sugar levels. Elastin is the main component of the elastic fiber in the skin. It works together with collagen and hyaluronic acid (HA) to maintain skin elasticity. Elastin extracted from the horse nuchal ligament contains large quantities of desmosine and isodesmosine that can smooth wrinkles, hydrate, whiten and repair the skin, plump the breasts, and lift the hips; therefore it's widely applied in food, drinks, cosmetics and skincare. As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health. Remaining steadfast in basic research, CABIO makes every effort to explore synthetic biology and biomedicine by mining the limitless potential consistently to offer quality ingredients and ready-to-market solutions to customers worldwide.Valuation Update With 7 Day Price Move • May 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥31.78, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Chemicals industry in China.Reported Earnings • Apr 14Full year 2022 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in FY 2021)Full year 2022 results: EPS: CN¥0.54 (down from CN¥1.07 in FY 2021). Revenue: CN¥433.4m (up 23% from FY 2021). Net income: CN¥64.4m (down 50% from FY 2021). Profit margin: 15% (down from 37% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Board Change • Mar 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cabio Biotech (Wuhan) は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XSSC:688089 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20264185597224N/A12/31/2025563144126270N/A9/30/202559617061241N/A6/30/2025601164-26167N/A3/31/2025595145-34163N/A12/31/2024556124-39173N/A9/30/2024506115-89150N/A6/30/2024506124-84173N/A3/31/2024473101-169118N/A12/31/202344491-22969N/A9/30/202348547-178118N/A6/30/202346149-150106N/A3/31/202344655-126107N/A12/31/202243364-73176N/A9/30/2022374105-104133N/A6/30/2022359111-96153N/A3/31/2022348118-66177N/A12/31/2021351129-70103N/A9/30/2021337121-3484N/A6/30/20213361272498N/A3/31/20213471393678N/A12/31/2020323131113146N/A9/30/2020317132152174N/A6/30/2020315126147161N/A3/31/2020301121145165N/A12/31/2019312118N/A132N/A9/30/2019318128N/A119N/A12/31/201828697N/A106N/A12/31/201722966N/A101N/A12/31/201619047N/A63N/A12/31/201518120N/A45N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 688089の予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 688089の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 688089の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 688089の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 688089の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 688089の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 04:23終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cabio Biotech (Wuhan) Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Li WuTianfeng Securities Brokerage Co., LtdJinsong FanZhongtai Securities Co. Ltd.
お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
お知らせ • May 24Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 15, 2026, at 14:00 China Standard Time. Location: No. 89, Hi-tech Park 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei China
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Dec 26Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Dec 03CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 ParisAt the 30th milestone edition of Food Ingredients Europe 2025, CABIO showcases its comprehensive nutritional ingredients portfolio while simultaneously announcing the official opening of its new Global Headquarter-Wuhan Synthetic Biology Innovation Hub, marking a pivotal leap forward in pioneering the future of synthetic biology. The hub embodies three core values: Deepening Innovation through an open platform uniting brilliant minds to explore synthetic biology's boundless potential; Strengthening Collaboration via dynamic spaces engineered to spark creativity and cross-disciplinary partnerships; and Amplifying Impact with advanced facilities and enhanced R&D capabilities to deliver greater value to global partners and drive sustainable industry growth. Five Core Product Lines: CABIO®?ARA delivers 20+ years of infant nutrition excellence. CABIO®?Omega-3 series, from sustainable microalgae, addresses needs from infant brain development to adult cardiovascular health. Keyshine®?HMOs 2'-FL utilizes advanced fermentation for breast milk-mimicking infant nutrition extending to adult wellness. Keyshine®?N-Acetylneuraminic Acid offers dual benefits for neurological development and skin health. Additionally, diversified application solutions provide customized partnerships across infant-to- adult nutrition spectrum. The new headquarter empowers CABIO's global expansion. With advanced R&D facilities and an open innovation platform, CABIO continues delivering premium, traceable nutritional ingredients to European and global partners, jointly driving sustainable development in nutrition and health industries. Visit CABIO's booth to explore unlimited possibilities in nutritional innovation.
お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
お知らせ • Jun 30Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2025 Results on Aug 19, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • May 08Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, May 29, 2025, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei China
お知らせ • Mar 28Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025
お知らせ • Jan 25Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 25 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.
お知らせ • Dec 27Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025
New Risk • Nov 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥25.10, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 30% over the past year.
Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.15 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.098 (down from CN¥0.15 in 3Q 2023). Revenue: CN¥126.3m (flat on 3Q 2023). Net income: CN¥16.0m (down 37% from 3Q 2023). Profit margin: 13% (down from 20% in 3Q 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥18.54, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Chemicals industry in China. Total returns to shareholders of 1.7% over the past year.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results.
お知らせ • Sep 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥17.55, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 9.0% over the past year.
New Risk • Sep 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results.
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.26 (up from CN¥0.13 in 2Q 2023). Revenue: CN¥143.8m (up 30% from 2Q 2023). Net income: CN¥43.6m (up 112% from 2Q 2023). Profit margin: 30% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Aug 28Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces an Equity Buyback for CNY 30 million worth of its shares.Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of its shares. The shares will be repurchased at no more than CNY 20 per share. The purpose of the program is to use the repurchased shares for equity incentive plan. If the company fails to complete the transfer within three years after the announcement of the results of the share repurchase and the share changes, the repurchased shares that have not been transferred will be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months.
New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (23% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥15.06, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 25% over the past year.
お知らせ • Jun 28Cabio Biotech (Wuhan) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • May 18Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024Cabio Biotech (Wuhan) Co., Ltd., Annual General Meeting, Jun 06, 2024, at 14:00 China Standard Time. Location: Meeting Room of the Company's Gedian Branch, Ezhou, Hubei China
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 34%After last week's 34% share price gain to CN¥19.65, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 11% over the past year.
Reported Earnings • Apr 28First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.086 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.086 in 1Q 2023). Revenue: CN¥117.0m (up 33% from 1Q 2023). Net income: CN¥24.3m (up 70% from 1Q 2023). Profit margin: 21% (up from 16% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
お知らせ • Mar 30Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024
Reported Earnings • Feb 26Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.39 in FY 2022)Full year 2023 results: EPS: CN¥0.54 (up from CN¥0.39 in FY 2022). Revenue: CN¥445.5m (up 2.8% from FY 2022). Net income: CN¥91.5m (up 42% from FY 2022). Profit margin: 21% (up from 15% in FY 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China.
New Risk • Feb 25New major risk - Revenue and earnings growthEarnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (9.7% net profit margin).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CN¥12.05, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 13x in the Chemicals industry in China.
お知らせ • Dec 29Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024Cabio Biotech (Wuhan) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024
Reported Earnings • Aug 26Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.17 in 2Q 2022). Revenue: CN¥111.0m (up 16% from 2Q 2022). Net income: CN¥20.5m (down 23% from 2Q 2022). Profit margin: 19% (down from 28% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • May 10Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023CABIO Biotech (Wuhan) Co., Ltd. announced on May 9 to 11, 2023, the company participates in the three-day Vitafoods Europe held in Geneva, Switzerland. The company showcases three new ingredients — HMOs, Salecan® ß-glucan and elastin — as well as its already well-known ARA, algal oil DHA, ß-Carotene and sialic acid (SA) during the exhibition. HMOs, human milk oligosaccharides in full, are the significant components of breast milk and play an essential part in promoting infant brain development, maintaining intestinal microecological balance, building resistance to bacteria and viruses, and improving immunoregulation. Adult ingestion of HMOs also enhances the quality of life by contributing positively to intestinal microbiota while likely improving severe symptoms of irritable bowel syndrome (IBS). Salecan® ß-glucan is a novel water-soluble ß-glucan generated from a patented strain using the fermentation process. Approved by both FDA-GRAS and Chinese FDA New Food Ingredient Accreditation, Salecan® ß-glucan is applied extensively in food & drinks, foods for special dietary uses (FSDUs) and dietary supplements to enhance immunity, regulate intestinal microbiota, repair intestinal mucosae and improve blood lipid and sugar levels. Elastin is the main component of the elastic fiber in the skin. It works together with collagen and hyaluronic acid (HA) to maintain skin elasticity. Elastin extracted from the horse nuchal ligament contains large quantities of desmosine and isodesmosine that can smooth wrinkles, hydrate, whiten and repair the skin, plump the breasts, and lift the hips; therefore it's widely applied in food, drinks, cosmetics and skincare. As the global expert in high-end nutrient and innovative solutions, CABIO has always dedicated itself to human nutrition and health. Remaining steadfast in basic research, CABIO makes every effort to explore synthetic biology and biomedicine by mining the limitless potential consistently to offer quality ingredients and ready-to-market solutions to customers worldwide.
Valuation Update With 7 Day Price Move • May 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥31.78, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Chemicals industry in China.
Reported Earnings • Apr 14Full year 2022 earnings released: EPS: CN¥0.54 (vs CN¥1.07 in FY 2021)Full year 2022 results: EPS: CN¥0.54 (down from CN¥1.07 in FY 2021). Revenue: CN¥433.4m (up 23% from FY 2021). Net income: CN¥64.4m (down 50% from FY 2021). Profit margin: 15% (down from 37% in FY 2021). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Board Change • Mar 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Xiangdong Chen was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.